medigraphic.com
Academia Mexicana de Neurología, A.C.

2005, Number 3

<< Back Next >>

Rev Mex Neuroci 2005; 6 (3)

Landry-Guillain-Barré-Strohl Syndrome. An update

Monroy GJ, Núñez OL

Language: Spanish
References: 84
Page: 271-282
PDF size: 170.25 Kb.


ABSTRACT

The Landry-Guillain-Barré-Strohl Syndrome, commonly known as Guillain Barré Syndrome (GB), is considered at present as a group of autoimmune illnesses, that are expressed as a polyradiculoneuropathic affection, that clinically is characterized as an ascending arreflectic cuadriparesis, with mild sensitive symptoms and sometimes autonomic alterations. Along with the clinical picture it is convenient to perform laboratory tests to confirm the diagnosis. In general, the treatment is symptomatic, specific and with rehabilitation with the aim of diminishing the morbimortality and the associated sequelae.


REFERENCES

  1. Dana I, et al. Guillain Barré syndrome. Am Fam Physician 2004; 69: 2405-10.

  2. Pascuzzi RM. Peripheral neuropathies in clinical practice. M Clin N Am 2003; 87: 3.

  3. Bonduelle M. Guillain Barré syndrome. Arch Neurol 1998; 55; 11: 1483-4.

  4. Tellería, A. Síndrome de Guillain-Barré. Rev Neurol 2002; 34: 954-66.

  5. Chio A, et al. A prospective, population-based study of long term outcome of Guillain Barré syndrome in Piemonte and Valle d’Aosta, Italy. Neurology 1999; 56; 6: A130-1.

  6. Chio A, et al. Guillain Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003; 60; 7: 1146-50.

  7. Hahn A. Guillain Barré syndrome. Lancet 1998; 352: 635-41.

  8. Ho TW, et al. Guillain Barré syndrome. Curr Opin Neurol 1999; 12; 4: 389-94.

  9. Anne J, et al. Guillain Barré syndrome. Adolesc Med 2002. 13: 487-94.

  10. Green D, et al. Mild Guillain Barré syndrome. Arch Neurol 2001; 58; 7: 1098-101.

  11. Van Koningsveld R, et al. Infections and course of mild forms of Guillain Barré syndrome. Neurology 2002; 58; 4.

  12. Ho TW, et al. Patterns of recovery in the Guillain Barré syndromes. Neurology 1997; 48; 3: 695-700.

  13. Fulgham J. Guillain Barré syndrome. Crit Care Clin 1997; 13(1).

  14. Hadden RDM. Preceding infections, immune factors, and outcome in Guillain Barré syndrome. Neurology 2001; 56: 6.

  15. Nishino S, et al. CSF hypocretin levels in Guillain Barré syndrome and other inflammatory neuropathies. Neurology 2003; 61; 6.

  16. Ropper A. Guillain-Barré syndrome. 1st Ed. F.A. Davis Co; 1991.

  17. Tsang R. The relationship of campylobacter jejuni infection and the development of Guillain Barré syndrome. Curr Opin Inf Dis 2002; 15: 221-8.

  18. Winer J. Treatment of Guillain Barré syndrome. QJM 2002; 95(11): 717-21.

  19. Yuki N. Infectious origins of a molecular mimicry in Guillain Barré and Fisher syndromes. Lan Inf Dis 2001; 1: 1.

  20. Carol A, et al. A review of the management of Guillain Barré syndrome in a regional neurological rehabilitation unit. Int J Reh Res 2003; 16: 297-302.

  21. Jacobs BC, et al. The spectrum of antecedent infections in Guillain Barré syndrome: a case-control study. Neurology 1998: 51; 4.

  22. Emilia-Romagna Study group on clinical and epidemiological problems in neurology. A prospective study on the incidence and prognosis of Guillain-Barré syndrome in Emilia-Romagna region, Italy (1992-1993). Neurology 1997; 48(1).

  23. Fletcher D, et al. Long-term outcome in patients with Guillain Barré syndrome requiring mechanical ventilation. Neurology 2000; 54; 12: 2311-5.

  24. Hahn A. The challenge of respiratory dysfunction in Guillain Barré syndrome. Arch Neurol 2001; 58; 6: 871-2.

  25. Lawn N, et al. Anticipating mechanical ventilation in Guillain Barré syndrome. Neurology 1999; 52; 6: A512-3.

  26. Lawn N, et al. Anticipating mechanical ventilation in Guillain Barré syndrome. Arch Neurol 2001; 58; 6: 893-8.

  27. Lawn N, et al. Fatal Guillain Barré syndrome. Neurology 1998; 50; 4: A242.

  28. Lawn N, et al. Fatal Guillain Barré syndrome. Neurology 1999; 52; 3: 635-8.

  29. Sharshar T, et al. Early predictors of mechanical ventilation in Guillain Barré syndrome. Crit Care Med 2003; 31: 278-83.

  30. Society of critical care medicine. Predicting the duration of mechanical ventilation in Guillain Barré syndrome: a new index based on respiratory function tests. Crit Care Med 1999; 27(1S): A158.

  31. Chandra P, et al. Gabapentin for the treatment of pain in Guillain Barré syndrome: a double bild, placebo-controlled, crossover study. Anest Analg 2002; 95(6): 1719-23.

  32. Mukesh T, et al. Carbamezapine for pain management in Guillain Barré syndrome patients in the intensive care unit. Crit Care Med 2000; 28; 3: 655-8.

  33. Berciano J. Acute motor conduction block neuropathy: another Guillain Barré syndrome variant. Neurology 2004; 62: 6.

  34. Combarros O, et al. Taste loss as an initial symptom of Guillain Barré syndrome. Neurology 1996; 47; 6: 1604-5.

  35. Hoffman O, et al. SIADH as the first symptom of Guillain Barré syndrome. Neurology 1999; 53; 6: 1365.

  36. LaGanke C, et al. Does sensory Guillain Barré syndrome exist? Neurology 1998; 50; 4: A142-3.

  37. Oh S, et al. Sensory Guillain Barré syndrome. Neurology 2001; 56: 1.

  38. Samdani A, et al. Bilateral facial paralysis. Physical Med Reh 1997; 76(2): 170.

  39. Sanders G. A case of Guillain Barré syndrome presenting as ataxia. Am J Em Med 2004; 22: 2.

  40. Sususki K, et al. Acute facial diplegia and hyperreflexia: a Guillain Barré syndrome variant. Neurology 2004; 62: 5.

  41. Yee T, et al. Acute sensory neuropathy: a sensory form of Guillain Barré Syndrome? J Clin Neuromusc Dis 2001; 2: 135-8.

  42. Yuki N, et al. Ataxic Guillain Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher Syndrome. Neurology 2000; 54; 9: 1851-3.

  43. Yuki N. Axonal Guillain Barré syndrome subtypes: do we need more splinting? Neurology 2003; 61: 5.

  44. Yuki N, et al. Guillain Barré syndrome presenting with loss of taste. Neurology 2002; 58: 9.

  45. Gordon P, et al. Early Electrodiagnostic findings in Guillain Barré syndrome. Arch Neurol 2001; 58: 913-7.

  46. Kuwabara S, et al. Two patterns of clinical recovery in Guillain Barré syndrome with IgG anti-GM1 antibody. Neurology 1998; 51; 6: 1656-60.

  47. Lisak R. Liver functions in Guillain Barré syndrome. Neurology 1996; 47; 6: 1606.

  48. Oomes PG, et al. Liver function disturbances in Guillain Barré syndrome: a prospective longitudinal study in 100 patients. Neurology 1996; 46: 1:96-100.

  49. Nagaoka U, et al. Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome. Neurology 1996; 47; 6: 1601-2.

  50. Levin K. Variants and mimics of Guillain Barré syndrome. Neurologist 2004;10: 61-74.

  51. Haider NR, et al. Rehabilitation in Miller Fisher variant of Guillain Barré syndrome. Phys Med Reh 1998; 77; 2: 177-8.

  52. Mori M. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56(8).

  53. Donofrio P. Autonomic disorders. Neurologist. 2001; 7: 220-33.

  54. Low P. Autonomic neuropathies. Curr Opin Neurol 1998; 11(5): 531-7.

  55. Low P. Autonomic neuropathies. Curr Opin Neurol 2002; 15: 606-9.

  56. Abutaher Y, et al. Cardiac arrhythmias in patients with severe Guillain Barré syndrome. Neurology 1999; 52(Supp 2); 6.

  57. Flachenecker P, et al. Eyeball pressure testing in the evaluation of serious bradyarrithythmias in Guillain Barré syndrome. Neurology 1996; 47(1): 102-8.

  58. 58 Sulton L. A multidisciplinary care approach to Guillain Barré syndrome. Dim Crit Care Nursing 2001; 20(1): 16-22.

  59. Moulin DE, et al. Pain in Guillain Barré syndrome. Neurology 1997; 48(7): 328-31.

  60. Hartug HP, et al. Drains the roots: a new treatment for Guillain Barré syndrome? Neurology 2001; 57: 5.

  61. Bril V, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain Barré syndrome. Neurology 1996; 46(1):100-3.

  62. Hughes RAC, et al. Practice parameter: immunotherapy for Guillain Barré syndrome: report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2003; 61; 6.

  63. Rana S, et al. Intravenous immunoglobulins vs. plasmapheresis in older patients with Guillain Barré syndrome. J Am Ger Soc 1999; 47; 11.

  64. Van Doorn PA, et al. Treatment of immuneneuropathies. Curr Opin Neurol 2002; 15: 623-31.

  65. Van Doorn PA. Immunotherapy for Guillain Barré syndrome. Lanc Neur 2004; 3: 2.

  66. Van Koningsveld R, et al. Changes in referral pattern and its effect on outcome in patients with Guillain Barré syndrome. Neurology 2001; 56: 564-6.

  67. Hughes R, et al. Systematic review of corticosteroid treatment for Guillain Barré syndrome. Neurology 1999; 52(2): A127-8.

  68. Shahar E. Outcome of severe Guillain Barré syndrome in children: comparison between untreated cases versus gamma globulin therapy. Clin Neurophar 2003; 26(2): 84-7.

  69. Hahn A. Intravenous immunoglobulin treatment in peripheral nerve disorders-indications, mechanisms of action and side effects. Curr Opin Neurol 2000; 13: 575-82.

  70. Visser LH, et al. Prognostic factors of Guillain Barré syndrome after immunoglobulin or plasma exchange. Neurology 1999; 53(3): 598-604.

  71. Yuki N, et al. Minimal numbers of plasma exchanges need to reduce immunoglobulin in Guillain Barré syndrome. Neurology 1998; 51(3): 875-7.

  72. Sharief M, et al. IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain Barré syndrome. Neurology 1999; 52(9): 1833-8.

  73. Sater R. The use of intravenous immunoglobulin for neurological diseases. Neurology 1998; 51(6).

  74. Mori M. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 2002; 58(6).

  75. Giovanni V. Epidemiology of the Guillain Barré syndrome. Curr Opin Neurol 2001; 14: 606-13.

  76. Pritchard BM, et al. A randomized controlled trial of recombinant interferon-b 1a in Guillain Barré syndrome. Neurology 2003; 61: 1282-4.

  77. Wollinsky K, et al. CSF filtration is an effective treatment of Guillain Barré syndrome. Neurology 2001; 57: 5.

  78. Bernsen RAJAM, et al. Residual physical outcome and daily living 3 to 6 years after Guillain Barré syndrome. Neurology 1999; 53: 2.

  79. Delaney Y, et al. Bilateral crocodile tears in a patient with Guillain Barré syndrome. J Neuro-Opftalmol 2002; 22: 113-5.

  80. Meythaler J. Rehabilitation outcomes of patients who developed Guillain Barré syndrome. Phys Med Reh 1997, 76; 5: 411-9.

  81. Henderson RD, et al. The morbidity of Guillain Barré syndrome admitted to the intensive care unit. Neurology 2003; 60(1): 17-21.

  82. Hartung HP, et al. Acute immunoinflamatory neuropathy: update on Guillain Barré syndrome. Curr Opin Neurol 2002; 13: 371-7.

  83. Linenbaum Y. Treatment approaches for Guillain Barré syndrome and chronic inflammatory demyelinating polyrradiculoneuropathy. N Clin 2001; 19(1).

  84. Sater R, et al. Treatment of Guillain Barré syndrome with intravenous immunoglobulin. Neurology 1998; 51; 1: S9-15




2020     |     www.medigraphic.com